Balk S - Search Results

1

Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer.

Awasthi S, Berglund A, Abraham-Miranda J, Rounbehler RJ, Kensler K, Serna A, Vidal A, You S, Freeman MR, Davicioni E, Liu Y, Karnes RJ, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk S, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah K. Awasthi S, et al. Among authors: balk s. Clin Cancer Res. 2021 Jan 1;27(1):320-329. doi: 10.1158/1078-0432.CCR-20-2925. Epub 2020 Oct 9. Clin Cancer Res. 2021. PMID: 33037017 Free PMC article.

2

Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP. Fenton MA, et al. Among authors: balk sp. Clin Cancer Res. 1997 Aug;3(8):1383-8. Clin Cancer Res. 1997. PMID: 9815822

3

A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.

Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ. Ko YJ, et al. Among authors: balk sp. Clin Cancer Res. 2001 Apr;7(4):800-5. Clin Cancer Res. 2001. PMID: 11309325 Clinical Trial.

4

Biology of prostate-specific antigen.

Balk SP, Ko YJ, Bubley GJ. Balk SP, et al. J Clin Oncol. 2003 Jan 15;21(2):383-91. doi: 10.1200/JCO.2003.02.083. J Clin Oncol. 2003. PMID: 12525533 Review.

5

Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.

Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M. Rossi S, et al. Among authors: balk s. Mol Cancer Res. 2003 Aug;1(10):707-15. Mol Cancer Res. 2003. PMID: 12939396

6

Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.

Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ. Spentzos D, et al. Among authors: balk s. Clin Cancer Res. 2003 Aug 15;9(9):3282-7. Clin Cancer Res. 2003. PMID: 12960113 Clinical Trial.

7

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Stanbrough M, et al. Cancer Res. 2006 Mar 1;66(5):2815-25. doi: 10.1158/0008-5472.CAN-05-4000. Cancer Res. 2006. PMID: 16510604

8

Natural killer T cell-based cancer immunotherapy.

van der Vliet HJ, Balk SP, Exley MA. van der Vliet HJ, et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5921-3. doi: 10.1158/1078-0432.CCR-06-1392. Clin Cancer Res. 2006. PMID: 17062661 No abstract available.

9

SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.

Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. Wang H, et al. Cancer Res. 2007 Jan 15;67(2):528-36. doi: 10.1158/0008-5472.CAN-06-1672. Cancer Res. 2007. PMID: 17234760

10

Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.

van der Vliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, Rudensky AY, Atkins MB, Balk SP, Exley MA. van der Vliet HJ, et al. Clin Cancer Res. 2007 Apr 1;13(7):2100-8. doi: 10.1158/1078-0432.CCR-06-1662. Clin Cancer Res. 2007. PMID: 17404092 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

398 results

Search Page

Filters